New insights into innate immune restriction of West Nile virus infection by Lazear, H.M. & Diamond, M.S.
New Insights into Innate Immune Restriction of West Nile Virus 
Infection
Helen M. Lazeara and Michael S. Diamonda,b,c,d,*
aDepartment of Medicine, Washington University School of Medicine, St Louis, MO 63110, USA
bDepartment of Molecular Microbiology, Washington University School of Medicine, St Louis, MO 
63110, USA
cDepartment of Pathology and Immunology, Washington University School of Medicine, St Louis, 
MO 63110, USA
dCenter for Human Immunology and Immunotherapy Programs, Washington University School of 
Medicine, St Louis, MO 63110, USA
Abstract
West Nile virus (WNV) is an encephalitic flavivirus that has provided a valuable experimental 
system for studying viral pathogenesis and immunity. Although in vitro approaches and mouse 
models of infection have identified pattern recognition receptor and interferon pathways that 
control WNV infection, our appreciation of specific antiviral effectors has been more limited. In 
this review, we highlight recent advances in our understanding of the host factors that restrict 
WNV infection in mammals and insects, especially those resulting from large-scale screening 
approaches.
Introduction
West Nile virus (WNV) is an encephalitic flavivirus that is maintained in an enzootic cycle 
between Culex mosquitoes and birds [1,2], and is transmitted to humans and other 
vertebrates as incidental, dead-end hosts [3]. This biology has interesting implications for 
virus-host interactions and human disease: since humans do not transmit WNV to 
mosquitoes, selective pressure from the human immune response does not drive WNV 
evolution or impact virus transmission in nature. WNV infection provides an excellent 
model for understanding virus-host-vector interactions, due to its high level of infectivity in 
mammalian and insect cells in culture, the availability of mouse models that mimic features 
of human disease, and its importance as a zoonotic agent of human and animal disease.
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After its initial introduction into New York City in 1999, WNV rapidly spread across the 
continental United States and by 2004 had become endemic in most parts of the country [4]. 
Its importance as an ongoing public health concern is demonstrated by recent outbreaks of 
WNV encephalitis, including a large outbreak in Texas in 2012 [5], the spread of a lineage 2 
strain across Europe since 2008 [6,7], and the emergence in Australia in 2011 of encephalitis 
caused by the Kunjin strain of WNV [8]. The latter two are examples of human disease 
caused by WNV strains that had rarely been associated with neuroinvasive disease in the 
past. Although the basis for the emergence of human disease from previously attenuated or 
avirulent WNV strains remains unclear, these outbreaks highlight the continued importance 
of understanding the biology of WNV pathogenesis and its interaction with its hosts.
WNV infection paradoxically is restricted by the DNA sensor cGAS
Several studies have shown that WNV infection is detected by pattern recognition receptors 
(PRRs) in the Toll-like receptor (TLR) and RIG-I-like receptor (RLR) families of RNA 
sensors [9–17] (Figure 1). However, recent studies have revealed that cGAS [18] and its 
downstream signaling molecule, STING [19] also restrict WNV infection. These 
observations were unexpected because cGAS is a DNA-sensing PRR, and had not been 
reported to control RNA virus infection [20]. Nonetheless, ectopic expression of cGAS 
inhibited WNV replication and cGAS−/− mice exhibited increased lethality after WNV 
infection [18]. cGAS signals through the adaptor molecule STING to induce type I 
interferon (IFN-α/β) production [20]. Consistent with a possible role for cGAS in controlling 
WNV infection, STING−/− mice also exhibited increased lethality after WNV infection [19], 
although this could be explained by cross-talk between STING and RLR signaling pathways 
[21]. The mechanism by which cGAS becomes activated following WNV infection remains 
unknown, but possibilities include: viral RNA-binding activity of cGAS, production of 
cDNA copies of viral sequences by cellular reverse transcriptases [22], or generation of host 
cell-derived DNA damage-associated molecular patterns (DAMPs) in response to cytopathic 
effects of virus infection [23].
Genetic screens identify IFN-induced antiviral effector molecules against 
WNV
Similar to many other RNA and DNA viruses, IFN-α/β is critical for controlling WNV 
infection and limiting pathogenesis (Figure 1). Early studies used Ifnar−/− mice to 
demonstrate an essential role for IFN-α/β in controlling WNV [24,25], but the specific 
mechanisms through which this antiviral effect was exerted remained unknown. IFN-α/β 
signaling induces the expression of hundreds of IFN-stimulated genes (ISGs), and while 
these presumably encode the effector molecules of an antiviral response, until recently 
inhibitory mechanisms had been described for only a few ISGs (e.g. Mx1, PKR, RNase L, 
and OAS) [26,27]. One of the key recent advances in our understanding of host factors that 
restrict WNV (as well as many other viruses) has been the application of large-scale ectopic 
expression [28,29] or gene silencing [30,31] screens to identify sets of genes that control 
viral replication in vitro. Such approaches have detected previously described components 
of the antiviral response (e.g. MDA5, RIG-I, TLR-3, MAVS, IRF-3, JAK2, STAT-2, IRF-9, 
and PKR) but also have revealed many novel antiviral ISGs, thereby identifying promising 
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targets for subsequent mechanistic studies and possible drug development. ISGs that 
displayed significant antiviral activity against WNV in vitro include: C6orf150, DDX24, 
HPSE, IFI44L, IFI6, IFITM2, IFITM3, IFRD1, IL13RA1, ISG20, MAFK, NAMPT, PAK3, 
PHF15, SAMD9L, SC4MOL, and viperin. The antiviral mechanisms of some well-
described ISGs have been reviewed [27,32], but the mechanisms by which these novel ISGs 
restrict WNV replication and their roles in controlling WNV pathogenesis remain to be 
determined. ISGs for which antiviral activity against WNV has been demonstrated in vivo 
include PKR, RNase L, viperin, and IFIT2 [33–36], several of which control WNV infection 
specifically in neurons of the central nervous system (CNS). Systems biology approaches 
will be critical for developing testable hypotheses from these complex datasets [37]. Indeed, 
a recent systems biology analysis of WNV infection in vivo revealed novel cross-talk 
between the RLR and IFN signaling pathways and the induction of inflammatory cytokines, 
as well as an unexpected role for natural killer cells in restricting WNV tropism [38].
There are several limitations to consider when interpreting large-scale ISG screens (Figure 
2), particularly given the apparent lack of overlap in the sets of antiviral genes identified by 
different investigators [28–31]. First, as ISGs normally are co-induced by similar stimuli, a 
single ISG expressed in isolation (e.g. ectopic expression) may lack interactions with and 
regulation by other ISGs that are present in the context of a viral infection. Some ISGs may 
be active only under particular circumstances (cell type, stage of virus infection, expression 
of other infection-induced factors) and the effect any individual ISG may be small. The 
modest antiviral effects observed for most ISGs suggest that these molecules act in concert 
to produce a cellular environment that is refractory to viral replication. Second, large-scale 
screens have been conducted in cell lines with defective antiviral responses, (e.g. Huh7, 
HeLa, or STAT1−/− fibroblasts). The dominant antiviral effector genes in these cells may 
not reflect those controlling viral replication in immune competent cells and tissues. Of 
particular relevance to WNV are antiviral effector molecules that are active in myeloid cells 
or neurons, the primary targets for WNV in vivo [1]. This issue is of great interest given 
recent studies demonstrating that the cerebral cortex and cerebellum have different basal 
levels of ISG expression and differential IFN responsiveness [39]. Specifically, tissue-
specific epigenetic modifications result in relatively higher basal levels of ISG expression in 
neurons of the cerebellum compared to the cortex, although the upregulation of ISG 
expression is more evident in the cortex. The end-result is that cerebellar neurons are more 
resistant to infection by WNV and other RNA viruses [39]. These findings highlight cell- 
and tissue-specific differences in the antiviral response, which are critical for understanding 
viral tropism and the antiviral response in vivo. Third, ISG screens generally have been 
conducted using virulent strains of WNV. Since viral pathogenesis likely reflects an ability 
to overcome key immune restrictions, virulent strains may antagonize or avoid the antiviral 
effects of some ISGs in vitro. In fact, critical antiviral restriction factors might be missed by 
this approach, since stronger antiviral effects produce greater selective pressures for viral 
immune evasion. Therefore, attenuated virus strains may be useful as probes to identify 
novel antiviral restriction factors. As an example, a virulent strain of WNV commonly used 
for pathogenesis studies exhibited no phenotype in IFIT1−/− primary cells or mice; the role 
of IFIT1 as an antiviral effector was revealed by an attenuated genetic mutant virus that 
lacked 2′-O methylation of its viral RNA cap structure [34,40].
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IFNs limit WNV neuroinvasion by tightening the blood-brain barrier
IFN-α/β has been thought to control WNV and other viruses by two primary mechanisms: i) 
the induction of cell-intrinsic antiviral effectors that restrict different steps in virus 
replication and ii) modulation of the adaptive immune response. Recent work suggests that 
IFN-α/β may act by an additional, novel mechanism: controlling blood-brain barrier (BBB) 
permeability [41]. The BBB is a physical barrier formed by tight junctions between 
endothelial cells in the CNS microvasculature, with input from astrocyte foot processes. The 
BBB protects vulnerable CNS tissues from harmful substances in the peripheral circulation, 
including viruses [42]. Following inoculation by a mosquito, WNV infects keratinocytes and 
resident dendritic cells in the skin [43], traffics to draining lymph nodes, and establishes 
infection in other myeloid cells, which results in viremia [1]. WNV and other encephalitic 
flaviviruses cause CNS disease when they breach the BBB and infect neurons in the brain 
and spinal cord. The mechanisms by which WNV crosses the BBB remain unclear, but 
could include transit of free virions across a compromised barrier, trafficking of infected 
leukocytes from the periphery, or direct infection of the endothelial cells that comprise the 
BBB [44]. One study found that inflammatory cytokine production downstream of TLR3 
signaling promoted BBB opening and WNV neuroinvasion [45], although a subsequent 
paper identified a protective role for TLR3 in limiting WNV pathogenesis [9]. Recent work 
has used in vivo and in vitro models to demonstrate that IFN-α/β signaling induces BBB 
tightening, thereby restricting WNV neuroinvasion. This tightening effect is rapid and 
involves rearrangement of endothelial cell junction proteins via Rho-Rac signaling pathways 
[41].
The insect antiviral response to WNV
While much attention has been given to the host response to WNV in humans and mice, 
there is a growing understanding of the insect antiviral response to arthropod-borne viruses, 
including WNV. The need to cycle between bird and mosquito hosts imposes evolutionary 
constraints on WNV, including selection for viruses that are non-pathogenic in mosquitoes 
[46, 47]. In addition to replicating in distinct cellular environments (e.g. temperature and 
lipid composition), WNV must evade both vertebrate and insect antiviral responses, 
including IFN and RNA interference (RNAi), respectively [48,49].
Drosophila systems have provided valuable models for understanding the insect response to 
viral infections, due to the wealth of genetic, developmental, and technical resources 
available [50]. Advantages of studying antiviral restriction factors in Drosophila include the 
ease with which cells in culture take up exogenous dsRNA, the availability of gene silencing 
reagents including whole-genome silencing screens, and the ability to validate in vitro 
findings in an animal model using existing mutant fly strains or rapidly generating new 
mutants of interest. A recent gene silencing screen in Drosophila DL1 cells identified 
putative WNV restriction factors; 86% of these have a human ortholog, suggesting 
commonalities between the antiviral pathways in insects and mammals [51]. In particular, 
the genes dRUVBL2, Tip60, and XPO1 shared antiviral activity in Drosophila, mosquitoes, 
human cells, and mouse primary neurons. The restriction factors identified in this approach 
surprisingly were enriched for nuclear functions such as RNA metabolism and transcription, 
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suggesting that Drosophila-based screens may reveal novel pathways in cell-intrinsic 
antiviral immunity.
There has been an increasing ability to translate findings from Drosophila into the 
mosquitoes that serve as WNV vectors. For example, the secreted peptide Vago has antiviral 
activity in Drosophila [52], and recently was shown to restrict WNV infection in mosquito 
cells [53,54]. The inhibitory activity of Vago requires JAK-STAT signaling [53]. 
Furthermore, Vago production is induced in response to pathogen-sensing by Dicer-2, a 
DExD/H-box helicase that also initiates the antiviral RNAi response in insects and is 
homologous to mammalian RLRs [52,55]. Thus, while insects do not possess an IFN 
system, Vago may serve as an antiviral functional analog.
While Drosophila models have identified many host factors that are conserved in other 
insects and even in mammals, other studies have revealed mosquito restriction factors that 
were not evident from Drosophila-based approaches. For example, aae-miR-2940 is a micro 
RNA (miRNA) that promotes WNV replication and is downregulated by mosquito cells in 
response to WNV infection [56]. This miRNA is found in Aedes and Culex mosquitoes, but 
has no counterpart in Drosophila. Validation of Drosophila factors in mosquitoes, as well as 
characterizing mosquito-specific factors, will provide new insights into the interactions of 
WNV with its biologically relevant insect vectors.
Conclusions
Our knowledge of the host factors that control WNV infection has expanded greatly in 
recent years, due in part to the results of large-scale genetic screens to identify antiviral 
factors. Ongoing work is needed to translate lists of possible antiviral genes into testable 
hypotheses and to understand the mechanisms by which these factors limit viral 
pathogenesis in insects and mammals.
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• Genetic screens have identified host factors restricting WNV infection in cells
• WNV infection paradoxically is restricted by cGAS, a DNA sensor
• Interferon-α/β tightens the blood-brain barrier, which limits WNV 
neuroinvasion
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Figure 1. The IFN-mediated antiviral response to WNV
WNV infection is sensed by pattern-recognition receptors (PRRs) including RIG-I-like 
receptors (RIG-I, MDA5) and Toll-like receptors (TLR3, TLR7). These signal to activate 
IRF-family transcription factors, which induce IFN-β transcription and production. New 
evidence suggests that a DNA sensor, cGAS, also activates the antiviral response after WNV 
infection. IFN-α/β signals in an autocrine and paracrine manner to induce the expression of 
hundreds of IFN-stimulated genes (ISGs) that inhibit viral replication by a variety of 
mechanisms. Many ISGs have been shown to restrict WNV replication in vitro (a selection 
of which are listed), but few of these have confirmed roles in controlling WNV pathogenesis 
in vivo (e.g., PKR, IFIT2, viperin, and RNase L). Virulent strains of WNV evade the 
antiviral activity of IFIT1; only mutant viruses that lack 2′-O methylation on the 5′ cap 
structure of their viral RNA are restricted by IFIT1.
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Figure 2. Limitations of genetic screens to identify antiviral interferon-stimulated genes (ISGs)
Large-scale ectopic expression and gene silencing screens have provided new insights into 
the IFN-induced host factors that restrict infection by WNV and other viruses in vitro. 
However, the roles of these host factors in controlling WNV pathogenesis in vivo remain 
less clear, owing to several limitations of this approach. First, viral infection triggers global 
changes in cellular gene expression and produces an antiviral milieu that is absent in the 
context of ectopic expression of a single ISG. Second, the antiviral response in transformed 
or knockout cell lines used for genetic screens may not faithfully represent that found in 
differentiated and immune competent cells. Third, some restriction factors may remain 
undetected because their antiviral activities are antagonized by the virulent strain of virus 
used in the genetic screen.
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